Researchers are actively exploring multi-drug combinations that could help people with IPF hold onto their lung strength longer than current treatments allow.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
This week the IPF research database holds over 4,000 studies and 1,246 active clinical trials (real-world tests of new treatments on volunteers). Most recent papers in the system are broad medical research, but the overall pace of IPF science keeps growing. Researchers are looking at how scarring (the harmful thickening of lung tissue in IPF) connects to other conditions like heart and liver disease, which may open new treatment angles.
The AI tested hundreds of drug combinations and found its best result yet — a seven-drug mix that could keep FVC (forced vital capacity, basically how much air your lungs can hold) at 98.1%. Healthy lungs score 100%, so 98.1% is remarkably close to normal. The drugs include ones that calm scar-promoting signals in the body, plus metformin (a widely used diabetes pill that also fights inflammation) paired with nintedanib (an approved IPF drug).
One question to ask your lung doctor at your next visit: 'Are there any clinical trials combining nintedanib with anti-scarring or anti-inflammatory drugs that I might qualify for?'